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Abstract 
Objectives: Contemporary data are lacking with respect to the incidence rates of, 
factors associated with, and impact of cardiac arrest from ventricular fibrillation or 
tachycardia (VF-CA) on hospital survival in patients admitted with an acute 
coronary syndrome (ACS). The objectives of this multinational study were to 
characterize trends in the magnitude of in-hospital VF-CA complicating an ACS 
and describe its impact over time on hospital prognosis. 
 
Methods: The study population consisted of 59,161 patients enrolled in the 
Global Registry of Acute Coronary Events Study between 2000 and 2007. 
Overall, 3,618 patients (6.2%) developed VF-CA during their hospitalization for 
an ACS. Incidence rates of VF-CA declined over time, albeit in an inconsistent 
manner. Patients who experienced VF-CA were on average older and had a 
greater burden of cardiovascular disease, yet were less likely to receive 
evidence-based cardiac therapies than patients in whom VF-CA did not occur. 
Hospital death rates were 55.3% and 1.5% in patients with and without VF-CA, 
respectively. There was a greater than 50% decline in the hospital death rates 
associated with VF-CA during the years under study. Patients with a VF-CA 
occurring after 48 hours were at especially high risk for dying during 
hospitalization (82.8%). 
 
   
Conclusions: Despite reductions in the magnitude of, and short-term mortality 
from, VF-CA between 2000 and 2007, VF-CA continues to exert a significant 
adverse effect on survival among patients hospitalized with an ACS. 
Opportunities exist to improve the identification and treatment of ACS patients at 
risk for VF-CA to reduce the incidence of, and mortality from, this serious 
arrhythmic disturbance. 
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PREFACE 
 
Data from the GRACE (Global Registry of Acute Coronary Events) Study, a large 
multinational sample of patients hospitalized with an ACS between 2000 and 
2007, was used to perform the analyses outlined herein.  
 
Dr. McManus wrote and designed the analyses outlined in this thesis. Wei Huang 
MS provided assistance with respect to performance of analyses and GRACE 
data management. Farhan Aslam MD, Parag Goyal MD, Joel Gore, MD, and 
Robert J. Goldberg PhD provided editorial assistance. 
 
 
CHAPTER I 
INTRODUCTION 
 
Cardiac arrest (VF-CA) is the leading cause of death in patients with 
coronary artery disease, and 450,000 deaths have been attributed to this 
arrhythmic disturbance annually in the U.S [1]. Despite marked improvements in 
the monitoring and treatment of patients hospitalized with an acute coronary 
syndrome (ACS), this patient population remains at especially high risk for the 
development of serious ventricular arrhythmias and VF-CA [2-5].  
Although the characteristics and treatment of patients hospitalized with an 
ACS have changed markedly during recent decades [2], contemporary data 
describing recent trends in the magnitude and impact of VF-CA in the setting of 
an ACS are lacking. Specifically, the increasing use of evidence-based 
medications and coronary revascularization procedures may have decreased the 
incidence of, and prognosis from, VF-CA in patients hospitalized with an ACS.[2] 
Prior studies suggest that timing of VF-CA may also have prognostic 
importance. As such, data are needed with respect to factors associated with the 
development of VF-CA and impact of the timing of VF-CA on hospital survival [3]. 
Data from the GRACE (Global Registry of Acute Coronary Events) Study were 
utilized to describe these and additional endpoints in a large multinational sample 
of patients hospitalized with an ACS between 2000 and 2007 [4,5]. 
  
   
CHAPTER II 
STUDY METHODS 
 
Details of the GRACE project and its data collection methods have been 
previously described [4,6,7]. In brief, this large multinational observational study 
was designed to reflect a representative patient population with ACS, irrespective 
of geographic region. A total of 113 hospitals located in 14 countries in North and 
South America, Europe, Australia, and New Zealand contributed data to this 
study.  
Adult patients (>18 years old) admitted with a presumptive diagnosis of 
ACS at participating hospitals were potentially eligible for study inclusion. 
Eligibility criteria included a clinical history of ACS accompanied by at least 1 of 
the following: electrocardiographic changes consistent with ACS, serial increases 
in biochemical markers of cardiac necrosis (CK-MB, creatine phosphokinase, or 
troponin), and documented coronary artery disease. Patients with non-
cardiovascular causes for their clinical presentation were excluded. Where 
required, study investigators received approval from their local hospital ethics or 
institutional review boards for the conduct of this study.  
Patients were identified through the use of active and passive disease 
surveillance at participating study sites. Patient medical records were reviewed 
for pertinent information in a retrospective manner by trained study coordinators 
using standardized case report forms. Demographic characteristics, medical 
   
history, presenting symptoms, biochemical and electrocardiographic findings, 
treatment practices, and hospital outcome data were collected. Standardized 
definitions of all patient-related variables, clinical diagnoses, and hospital 
complications and outcomes were used. A GRACE risk score was calculated 
based on an 8-variable model previously developed and validated [6,10,11]. 
All ACS cases were assigned to 1 of the following categories using 
standardized definitions: ST-segment elevation myocardial infarction (STEMI), 
non-ST-segment elevation myocardial infarction (NSTEMI), or unstable angina 
(UA) [8,9]. The STEMI category included patients with at least 1 positive cardiac 
biochemical marker of necrosis (including troponin measurements) and new or 
presumed new ST-segment elevation ≥1 mm seen in any location, or new left 
bundle branch block on the index or subsequent ECG. Patients were considered 
to have a NSTEMI if they had at least 1 positive cardiac biochemical marker of 
necrosis without new ST-segment elevation seen on the index or subsequent 
ECG. Unstable angina was considered to be present when serum biochemical 
markers indicative of myocardial necrosis were within the normal range. 
Complete definitions of these variables and other factors can be found on the 
GRACE web site at www.outcomes.org/grace. 
Cardiac arrest from ventricular fibrillation or tachycardia was defined as 
any episode of ventricular tachycardia or fibrillation requiring resuscitation 
(external cardiac massage or direct current cardioversion or both). Early VF-CA 
was defined as that occurring on presentation or within the first 48 hours of 
   
hospitalization, whereas late VF-CA occurred after this time; these cutpoints 
have been previously utilized in the published literature [3]. Patients with more 
than 1 episode of VF-CA were categorized on the basis of their initial episode.  
 
Data Analysis 
Differences in the characteristics and hospital outcomes of patients who 
developed VF-CA compared to those who did not were compared using chi 
square tests or Fisher’s exact test of statistical significance for discrete variables. 
Continuous variables were analyzed using t tests and the Wilcoxon rank-sum test. 
Differences in the characteristics and hospital outcomes of patients who 
developed early VF-CA compared to those who developed this arrhythmia after 
48 hours of hospitalization were compared in a similar fashion. 
Variables considered for inclusion in our regression models were baseline 
demographic characteristics (age, sex), medical history (angina, myocardial 
infarction, heart failure, percutaneous coronary intervention, coronary artery 
bypass graft surgery, diabetes, hypertension, and hyperlipidemia), and hospital 
presentation characteristics (blood pressure, pulse, Killip class, ST-segment 
deviation, initial cardiac markers, initial serum creatinine). Our hospital endpoints 
included adverse cardiac events, including recurrent ischemic/anginal symptoms, 
heart failure, non-cardiac adverse events (renal failure, stroke, major bleeding), 
and survival status at the time of hospital discharge.   
 
   
CHAPTER III 
STUDY FINDINGS 
 
 A total of 59,261 patients were enrolled in this coronary disease registry 
between 2000 and 2007 and constituted the sample of the present report. The 
mean age of study participants was 65.7 years, 67.3% were men, 29.9% had a 
history of prior myocardial infarction, and 36.7% presented with a STEMI.  
 
Incidence Rates of Cardiac Arrest  
Between 2000 and 2007, a total of 3,618 patients (6.2%) developed VF-
CA during their index hospitalization for an ACS. The incidence rates of VF-CA 
varied significantly by ACS type, with 10.5% of patients with STEMI, 4.3% of 
patients with NSTEMI, and 2.9% of patients with UA developing this arrhythmic 
complication (p < 0.001). The incidence rates of VF-CA declined during the years 
under study, albeit in an inconsistent manner (Figure 3.1). The greatest decline 
in VF-CA occurred between 2000 (6.8%) and 2002 (5.7%). 
 
Baseline Characteristics of Study Sample 
Patients who developed VF-CA were on average older and were more 
likely to have higher average GRACE risk and Killip class scores, a higher 
maximum troponin level, a lower ejection fraction, a longer hospital stay, a history 
of heart failure, and present with a STEMI at the time of hospital admission in 
   
comparison to patients who did not develop VF-CA during their acute 
hospitalization (Table 3.1). 
On the other hand, ACS patients who did not develop VF-CA had a higher 
body mass index, higher blood pressure, and lower initial heart rate on 
presentation, and were more likely to have a history of smoking, hypertension, 
dyslipidemia, or prior coronary artery disease than ACS patients who 
experienced a VF-CA. Patients in whom VF-CA did not occur were also more 
likely to have previously undergone a percutaneous coronary intervention and 
coronary artery bypass graft surgery. The proportion of patients with implantable 
cardioverter-defibrillators did not differ between the respective comparison 
groups. 
 
Outpatient and Hospital Treatment Practices  
 Patients who experienced a VF-CA were significantly less likely than those 
who did not experience a VF-CA to report outpatient use of aspirin, beta-blockers, 
statins, and angiotensin converting enzyme (ACE) inhibitors (Table 3.2). Patients 
who developed VF-CA during hospitalization were slightly more likely to be 
prescribed amiodarone as an outpatient than were patients who did not develop 
this ventricular arrhythmia. 
 Patients with VF-CA were also less likely than patients without this 
arrhythmic complication to have received evidence-based cardiac treatments 
during their hospitalization, including aspirin, beta-blockers, statins, and ACE 
   
inhibitors (Table 3.2). Utilization of percutaneous coronary intervention did not 
differ between our 2 primary comparison groups whereas the in-hospital 
prescription of thrombolytics, amiodarone, and inotropes was more common 
among patients with VF-CA. Patients with VF-CA were more likely to have 
undergone coronary artery bypass surgery and intra-aortic balloon pump 
placement during their hospital stay as compared to those who did not develop 
VF-CA. 
 
Hospital Complications 
Patients who experienced a VF-CA were more likely than patients who did 
not develop this arrhythmic complication to have developed recurrent cardiac 
ischemia, cardiogenic shock, atrial fibrillation/flutter, heart failure, renal failure, 
stroke, and major bleeding during their hospitalization (Table 3). A multiple 
logistic regression analysis was carried out to examine the association of VF-CA 
with each of these in-hospital complications while controlling for a variety of 
factors known to affect the development of these endpoints in patients 
hospitalized with an ACS. The odds of developing recurrent cardiac ischemia, 
cardiogenic shock, heart failure, stroke, renal failure, and major bleeding 
remained substantially higher among patients with VF-CA after adjustment for 
several potentially confounding factors (Table 3.3). 
 
In-Hospital Mortality 
   
As expected, the in-hospital case-fatality rate (55.3%) and multivariable 
adjusted odds of dying during hospitalization for an ACS were markedly higher 
among patients with an ACS complicated by VF-CA than it was among patients 
who did not develop VF-CA (Odds Ratio 75.5, 95% Confidence Interval 66.2-
86.0). Death rates among patients with in-hospital VF-CA were significantly 
higher than would have been expected (8.4%) on the basis of their GRACE Risk 
score (175), whereas in-hospital death rates among participants without VF-CA 
(1.5%) were similar to those predicted on the basis of their GRACE Risk Score 
(1.9%, 130). Mortality rates from VF-CA showed an inverse relation with ACS 
severity, as 66.4% of patients with UA, 59.8% of patients with NSTEMI, and 51.1% 
of patients with STEMI died during their hospitalization. During the period that in-
hospital mortality decreased only slightly among patients without VF-CA, in-
hospital mortality declined markedly among patients with VF-CA (from 70.8% in 
2000 to 41.1% in 2007, p <0.001, Figure 3.2) [10].”  
 
Impact of Timing of Cardiac Arrest on Hospital Prognosis 
 To explore the impact of timing of VF-CA on short-term prognosis, a 
separate analysis was carried out using data from 2,167 patients for whom timing 
of VF-CA was recorded (60% of patients with VF-CA, Table 3.4). Patients with 
late VF-CA (n=527) were on average older and more likely to have a history of 
cardiovascular disease and its risk factors than patients who suffered a VF-CA 
early during their hospitalization (n=1,640). Patients with NSTEMI were more 
   
likely than those with STEMI to experience a VF-CA at a later time during their 
hospitalization (33.3% vs. 20.9% of VF-CA, p <0.001). On the other hand, 
patients with late VF-CA were less likely to currently smoke cigarettes and had a 
slightly lower average GRACE Risk Score as well as body mass index. 
 Patients with late VF-CA experienced, on average, a longer hospital stay 
and were more likely to have developed clinically significant in-hospital 
complications including recurrent angina, myocardial infarction, heart failure, 
cardiogenic shock, atrial fibrillation, renal failure, and major bleeding episodes 
than patients who developed VF-CA early during their acute hospital admission 
(Table 3.5). A significantly greater proportion of patients with late VF-CA died 
during hospitalization compared with patients who experienced VF-CA during the 
first 48 hours of hospitalization (83% vs. 39%, p <0.001). 
  
   
Figure 3.1. Trends in the Incidence Rates of Cardiac Arrest (GRACE)
 
Figure 3.1 Legend. Incidence rates of VF-CA between 2000 and 2007 in the 
GRACE study. 
  
   
Table 3.1. Baseline Characteristics of GRACE Participants with and without 
Cardiac Arrest 
Variable* Cardiac Arrest 
Present(+) 
(n=3,618) 
Cardiac Arrest 
Absent (-) 
(n=55,149) 
p-value 
 
Age (years) 
 
68.8 (13.6) 
 
65.5 (13.2) 
 
<0.001 
Male 2340 (65%) 37067 (68%) 0.002 
Body Mass index 
(kg/m2) 
26.9 (5.3) 27.7 (5.4) <0.001 
Systolic BP (mmHg) 124.7 (37.0) 142.4 (29.0) <0.001 
Diastolic BP (mmHg) 73.2 (23.0) 80.4 (17.6) <0.001 
Pulse (bpm) 84.5 (27.4) 79.1 (20.8) <0.001 
GRACE Risk Score 175.2 (44.8) 129.5 (35.6) <0.001 
Killip class III and IV 696   (20%) 2073 (3.8%) <0.001 
Length of stay (days) 8.2 (10.2) 7.2 (7.3) <0.001 
Medical History 
   
   Smoking 1917 (54%) 31695 (58%) <0.001 
   Diabetes 942 (26%) 13785 (25%) 0.11 
   Hypertension 2113 (59%) 34241 (62%) <0.001 
   Dyslipidemia 1338 (38%) 27039 (49%) <0.001 
   Angina 1550 (44%) 28161 (53%) <0.001 
   AF 4110 (7.5%) 3562 (9.3%) <0.001 
   MI 941 (26%) 16551 (30%) <0.001 
  PCI 368 (10%) 10091 (18%) <0.001 
 CABG 325 (9.1%) 6893 (13%) <0.001 
 Heart Failure 508 (14%) 5348 (9.8%) <0.001 
 ICD 15 (0.7%) 257 (0.8%) 0.78 
 
AMI Type 
   
 ST elevation MI 2256 (62%) 19317 (35%) <0.001 
<0001  Non ST elevation MI 849 (23%) 18880 (34%) 
 Unstable angina 513 (14%) 16952 (31%) 
 
Laboratory 
   
   Creatinine (mg/dL) 1.4 (1.1) 1.2 (0.8) <0.001 
   Total cholesterol 
(mg/dL) 
184.4 (54.6) 190.7 (49.4) <0.001 
   Troponin** 45.6 (99.3) 21.6 (63.6) <0.001 
   Baseline EF (%)*** 41.2 (15.7) 50.8 (14.3) <0.001 
   LBBB 251 (6.9%) 2576 (4.5%) <0.001 
   
Table 3.1 Legend 
* Mean (± SD), laboratory values obtained from admission 
** Maximum value within first 24 hours. Upper limit of normal troponin did not 
vary between groups (median 0.1, interquartile range 0.1-0.4). 
*** Ejection fraction was measured in 43% of patients with VF-CA and 48% of 
patients without VF-CA 
BP = blood pressure; AF = atrial fibrillation; MI = myocardial infarction; PCI = 
Percutaneous coronary intervention; CABG = coronary artery bypass graft; ICD = 
implantable cardioverter defibrillator; CAD = coronary artery disease; EF = 
ejection fraction; LBBB = left bundle branch block 
  
   
Table 3.2 Outpatient and In-Hospital Treatments in GRACE Participants 
Stratified by Development of In-Hospital Cardiac Arrest 
Treatment* Cardiac Arrest 
Present (+)  
(n=3,618) 
Cardiac Arrest 
Absent (-) 
(n=55,149) 
p-value 
Chronic    
    Aspirin 1044 (29%) 22354 (40.6) <0.001 
    Beta-blocker 877 (24.4%) 18369 (33.5%) <0.001 
    ACE inhibitor 890(24.9%) 15573 (28.4%) <0.001 
    Statin 657 (17.5%) 15685 (28.6%) <0.001 
    Omega-3 FA 9 (0.4%) 217 (0.6%) 0.21 
    Amiodarone 85 (2.4%) 997 (1.8%) 0.02 
 
In-hospital    
    Aspirin 3049 (85%) 51806 (94%) <0.001 
    Beta-blocker 2370 (66%) 47032 (86%) <0.001 
    ACE inhibitor 2080 (58%) 36452 (67%) <0.001 
    Statin 1794 (50%) 38841 (71%) <0.001 
    Amiodarone** 681 (19.1%) 2027 (3.7%) <0.001 
    Inotrope** 1247 (34.9%) 1600 (3.0%) <0.001 
 
Procedures    
   PCI 1395 (38.8%) 21559 (39.4%) 0.51 
   Thrombolytics 796 (22.2%) 6822 (12.5%) <0.001 
   CABG 225 (6.3%) 2766 (5.1%) 0.002 
   IABP 505 (14.3%) 1064 (2.0%) <0.001 
 
Table 3.2 Legend 
* Mean (± SD) 
** Within the first 24 hours of hospitalization 
ACE= Angiotensin converting enzyme; FA = Fatty acid; PCI = Percutaneous 
intervention; CABG = coronary artery bypass surgery; IABP = intra-aortic balloon 
pump 
  
   
Table 3.3 Hospital Complications According to the Presence of Cardiac 
Arrest 
 
Complication* Cardiac Arrest 
Present (+) 
(n=3,618) 
 Cardiac Arrest 
Absent (-) 
(n=55,149) 
Adjusted** Odds of 
Complication 
 
Recurrent Ischemic 
Symptoms (Angina) 
1090 (31%) 12412 (23%) 1.7 (1.5-1.8) 
Heart Failure 1431 (40%) 6326 (12%) 2.9 (2.7-3.2) 
Cardiogenic Shock 1373 (38%) 969 (1.8%) 16.8 (15-18.8) 
Atrial Fibrillation/Flutter 662 (19%) 3826 (7.0%) 2.0 (1.8-2.3) 
Renal Failure 641 (18%) 1642 (3.0%) 4.6 (4.0-5.2) 
Stroke 97 (2.7%) 327 (0.6%) 2.9 (2.2-3.9) 
Major Bleeding 232 (6.6%) 1122 (2.1%) 2.3 (1.9-2.7) 
 
Table 3.3 Legend  
* Unless otherwise indicated, new-onset complications 
** Adjusted for 8 independent variables used to calculate GRACE risk score, 
history of angina, myocardial infarction, heart failure, percutaneous coronary 
intervention, CABG, diabetes, hypertension, and hyperlipidemia. 
   
Table 3.4 Characteristics of GRACE Participants* Experiencing a Cardiac 
Arrest within as Compared to after 48 hours of Hospitalization 
 
Variable** Early Cardiac 
Arrest 
(n=1640) 
Late Cardiac 
Arrest (n=527) 
p-value 
 
Age (years) 
 
66.7 (13.9) 
 
74.1 (11.3) 
 
<0.001 
Male 1114 (68%) 340 (65%) 0.18 
Body Mass index 
(kg/m2) 
27.1 (5.0) 26.5 (4.9) 0.03 
Systolic BP (mmHg) 122.7 (36.7) 129.6 (31.0) <0.001 
Diastolic BP (mmHg) 72.9 (22.6) 74.3 (20.6) 0.87 
GRACE Risk Score 177 (46.8) 171 (37.8) 0.04 
Killip class III and IV HF 322 (20%) 90 (17%) <0.001 
Length of stay (days) 6.7 (8.8) 12.4 (12.2) <0.001 
 
Medical History 
   
   Smoking 894 (55%) 250 (48%) 0.004 
   Diabetes 380 (23%) 178 (34%) <0.001 
   Hypertension 941 (58%) 359 (69%) <0.001 
   Dyslipidemia 624 (38%) 235 (45%) 0.008 
   Angina 555 (34%) 254 (48%) <0.001 
   AF    
   MI 359 (22%) 179 (34%) <0.001 
   PCI 188 (12%) 63 (12%) 0.79 
   CABG 130 (8.0%) 76 (15%) <0.001 
   Heart Failure 150 (9.3%) 122 (23%) <0.001 
   ICD 9 (0.6%) 6 (1.2%) 0.22 
 
AMI Type 
   
   ST elevation MI 1069 (65%) 283 (54%) <0.001 
   Non ST elevation MI 353 (22%) 176 (33%) 
   Unstable angina 218 (13%) 68 (13%) 
 
Laboratory 
   
   Creatinine (mg/dL) 1.4 (1.0) 1.5 (1.1) <0.001 
   Total cholesterol 
(mg/dL) 
180.0 (51.7) 175.7 (57.0) 0.11 
   Troponin*** 45.4 (95.9) 46.2 (109.4) 0.07 
   Baseline EF (%) 42.6 (15.9) 38.7 (15.0) <0.001 
   LBBB 89 (5.4%) 45 (8.5%) 0.01 
   
 
Table 3.4 Legend. * Information on timing of cardiac arrest available on 2,167 
GRACE participants (60% of participants with VF-CA) 
** Mean (± SD), laboratory values obtained from admission 
*** Maximum value within first 24 hours. Upper limit of normal troponin did not 
vary between groups (median 0.1, interquartile range 0.1-0.4). 
BP = blood pressure; AF = atrial fibrillation; MI = myocardial infarction; PCI = 
Percutaneous coronary intervention; CABG = coronary artery bypass graft; ICD = 
implantable cardioverter defibrillator; CAD = coronary artery disease; EF = 
ejection fraction 
 
  
   
 
Table 3.5 In-Hospital Complications Among Grace Participants Stratified by 
Early (within 48 hours) vs. Late (after 48 hours) Cardiac Arrest 
 
Variable Early Cardiac Arrest 
(n=1640) 
 
Late Cardiac Arrest 
(n=527) 
p-value 
Recurrent Ischemic 
Symptoms (Angina) 
449 (28%) 286 (55%) <0.001 
Heart Failure 463 (29%) 298 (57%) <0.001 
Cardiogenic Shock 493 (30%) 258 (50%) <0.001 
Atrial Fibrillation/Flutter 232 (14%) 145 (28%) <0.001 
Renal Failure 173 (11%) 185 (36%) <0.001 
Stroke 37 (2.3%) 18 (3.5%) 0.13 
Major Bleeding 61 (4.0%) 55 (9.5%) <0.001 
Death 644 (39%) 434 (83%) <0.001 
 
  
   
 
CHAPTER IV 
DISCUSSION 
 
 The results of this large, multinational study demonstrate that VF-CA is an 
infrequent, but often fatal, complication of an ACS. The incidence of, and 
mortality from, VF-CA declined over the period under study, likely due to 
increased monitoring and better treatment of patients with an ACS as well as VF-
CA. Opportunities exist, however, for the enhanced prevention of VF-CA and its 
complications. 
 
Incidence of Cardiac Arrest 
Over a relatively recent study period, VF-CA developed in approximately 1 
in every 14 patients hospitalized with an ACS in our multinational coronary 
disease registry. The incidence rates of VF-CA observed in our study were 
significantly lower than those reported in a community-based study of individuals 
hospitalized with AMI between 1975 and 1984, in which 21% of patients 
developed VF-CA [11]. Reasons for the differences between our study and this 
prior study may include the more contemporary nature of the present 
investigation, higher utilization of chronic and in-hospital therapies known to 
reduce the odds of VF-CA, a greater proportion of patients with early VF-CA, and 
inclusion of patients with less severe forms of ACS in our study. These 
hypotheses were supported by our observation that patients with MI were more 
   
likely than those with UA to develop VF-CA in our study. In addition, a recent 
analysis examining the incidence rates of VF in a population-based study of 
central Massachusetts residents hospitalized with AMI reported declining rates of 
VF between 1995 and 2005, reaching levels (4.2%) more consistent with our 
findings (6.2%) and those of the National Registry of Myocardial Infarction-2 
(4.8%) [11-14]. 
Consistent with the published literature, clinical characteristics associated 
with poorer baseline cardiovascular health, larger infarct size, and worse 
disease-specific clinical status were associated with the development of VF-CA 
in the present investigation [13]. Interestingly, however, a history of several 
traditional cardiovascular risk factors, including hypertension, smoking, diabetes, 
and dyslipidemia, was not associated with an increased risk for VF-CA. These 
findings suggest that ACS severity places patients at higher risk for developing 
VF-CA, irrespective of the presence of established cardiovascular risk factors. 
 
Outpatient and Hospital Treatment Practices 
Outpatient and in-hospital use of effective cardiac medications known to 
reduce the risk of ventricular arrhythmias and improve prognosis from ACS, 
including aspirin, statins, ACE inhibitors, and beta-blockers, were less frequently 
utilized in ACS patients with VF-CA in comparison to patients who did not 
develop VF-CA. Use of thrombolytic medications was higher in the VF-CA group, 
perhaps due to the fact that patients with VF-CA were more likely to present with 
   
a STEMI or because these agents were administered as part of advanced 
cardiac life support efforts [15]. Chronic use of amiodarone was paradoxically 
higher among patients who experienced VF-CA compared to patients who did 
not experience VF-CA. Use of amiodarone to suppress non-sustained ventricular 
arrhythmias, or use of amiodarone to maintain sinus rhythm among patients with 
atrial fibrillation, a disease associated with a poor prognosis after an ACS, may 
partially explain this observation [16].  
Caution in interpreting our findings is warranted, however, since the 
under-utilization of evidence-based therapies among hospitalized patients with 
VF-CA may have been partially due to the fact that patients with VF-CA were 
hemodynamically unstable or had experienced complications that serve as 
contraindications to ACS treatments. In-hospital contraindications, however, do 
not explain outpatient prescription patterns nor do they discount the fact that an 
opportunity exists for enhanced primary prevention of VF-CA through application 
of evidence-based ACS treatments, such as beta-blockers, among patients 
hospitalized with an ACS based on the results of our large descriptive study.  
 
Hospital Complications 
 Patients who experienced a VF-CA during hospitalization for an ACS were 
at increased risk not only for developing recurrent cardiac ischemia, cardiogenic 
shock, and heart failure during their index hospitalization, but also renal failure 
and major bleeding episodes. Both major bleeding and renal dysfunction 
   
complicating AMI have been associated with increased mortality, perhaps 
through the observed association with malignant ventricular arrhythmias and VF-
CA [17,18]. These findings, as well as those from other studies, suggest that 
close attention should be directed to monitoring for, and appropriately treating, 
kidney injury, electrolyte abnormalities, and anemia in additional to traditional 
hemodynamic perturbations (e.g., tachycardia and hypotension) in hospitalized 
patients with an ACS. 
The incidence rates of VF-CA declined in our hospitalized patient 
population between 2000 and 2007, concomitant with the greater and timelier 
application of effective ACS treatments in this population [19-22]. Although our 
study design precludes an assumption of causality, early intervention with 
evidence-based cardiac medications and coronary revascularization in patients 
with myocardial injury has been shown to limit infarct size and reduce the risk of 
ventricular arrhythmias [23]; inasmuch, the increased use of these therapies may 
have exerted a beneficial effect on the occurrence of VF-CA in our study 
population over time [20-24]. In addition, increased cardiac monitoring and 
prophylactic treatment of ventricular arrhythmias with anti-arrhythmic medications 
may have reduced the incidence rates of VF-CA observed in the present study 
[25,26].  
 
Hospital Mortality in Patients with Cardiac Arrest 
   
 Previously reported in-hospital case-fatality rates for VF-CA complicating 
ACS vary widely, ranging from 24% to 78% [11-14,27]. The observed case-
fatality rate among hospitalized patients with VF-CA complicating ACS in our 
study (55%) is slightly higher than that previously reported in a large clinical 
investigation that included nearly 41,000 patients who were treated with 
thrombolytic therapy [26]. Use of more restrictive inclusion criteria in the context 
of a randomized controlled trial, as well as varying case definitions, partially 
accounted for differences in these findings, a theory supported by the fact that 
the hospital mortality rates observed in our study are much lower than those 
reported in 2 observational studies involving patients with AMI (78% and 71%) 
[11,13].  
 Although in-hospital death rates remained significantly elevated in patients 
experiencing VF-CA during the most recent years under study, improvements in 
hospital survival among patients with VF-CA were observed between 2000 and 
2007. Our observation that mortality rates declined by 51% during this period is 
notable in light of a 50% decline in death rates reported between 1993 and 2005 
in a separate study of patients with ventricular fibrillation complicating their 
hospitalization for AMI [14]. The present findings likely reflect the enhanced 
treatment of patients hospitalized with an ACS as well as improved, and timelier, 
treatment of VF-CA over time in our cohort [22,28].  
 
Impact of Timing of Cardiac Arrest on Short-Term Prognosis 
   
 Consistent with an emerging literature, VF-CA occurring within 48 hours of 
hospitalization for an ACS was associated with a more favorable prognosis than 
VF-CA occurring later during hospitalization, despite adjustment for potential 
confounders of prognostic importance [3,13,27,29]. Since patients with early and 
late VF-CA differed with respect to a number of factors known to affect in-hospital 
survival, we hypothesize that the etiology of, and prognosis after, VF-CA may 
differ between these groups. Our findings suggest that whereas transitory 
electrical instability due to myocardial ischemia, coronary reperfusion, electrolyte 
abnormalities, neurohormonal activation, and sympathetic nervous system up-
regulation may play a large role in the development of early VF-CA, extension of 
myocardial injury, ventricular scar formation, generation of sustained and 
refractory ventricular arrhythmias, sustained hemodynamic instability, and acute 
kidney injury may contribute to a larger extent in the development and impact of 
late VF-CA, thus placing patients with late VF-CA at greater risk for dying [30-36]. 
Cardiac arrest occurring later during a patient’s hospital stay may also reflect a 
failure of hemodynamic stabilization and/or coronary reperfusion, so-called 
“secondary” cardiac arrest. Last, patients who experienced VF-CA later during 
their hospitalization may have been less intensively monitored (e.g., out of the 
intensive care unit or off of cardiac telemetry), thereby delaying the institution of 
effective cardiac treatments. This hypothesis is supported by the very high 
mortality rate among patients with late VF-CA (83%). These results suggest that 
clinicians should continue their current aggressive coronary revascularization 
   
efforts in patients with an ACS in an effort to limit infarct extension and prevent 
pump failure, as well as be diligent in monitoring and treating patients who 
develop VF-CA at a later time during their hospitalization for an ACS. 
 
Study Strengths and Limitations 
The strengths of the present study include its multi-national design, large 
sample of patients hospitalized with independently validated ACS, and its 
relatively contemporary and changing perspective into the clinical epidemiology 
of ACS and VF-CA. As a nonrandomized observational study, however, GRACE 
is subject to inherent limitations, including missing or incomplete information, and 
potential confounding by drug indication or other unmeasured covariates. 
Although they represented a minority of enrolled individuals (2%), patients with 
CA on presentation (including potential cases of pulseless electrical activity or 
asystole) were included in the present study due to limitations in our data 
abstraction methods. Patients who died before reaching participating study 
hospitals were excluded, left ventricular ejection fraction was measured in less 
than one half of study patients, data on non-sustained ventricular tachycardia 
were not collected, use of anti-arrhythmic drugs, such as lidocaine, was not 
recorded, and timing of VF-CA development in relation to the receipt of coronary 
reperfusion or other cardiac therapies was not collected.  
  
   
CHAPTER V 
CONCLUSIONS 
 
  In this large multinational study, we have demonstrated that VF-CA is a 
relatively uncommon but frequently fatal complication in patients hospitalized with 
an ACS. Encouragingly, we observed declining incidence and case-fatality rates 
of VF-CA in our patient population, likely reflecting enhanced monitoring and 
treatment efforts over a recent 8-year period. Nevertheless, VF-CA remains 
associated with renal, cardiovascular, and hematologic complications as well as 
reduced in-hospital survival. Continued primary and secondary prevention efforts 
remain warranted in all patients hospitalized with an ACS, particularly in several 
high-risk groups that were identified in the present investigation.  
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